NCT04094961: Phase 1/2: Ixazomib + Pomalidomide + Dexamethasone In MM

NCT04094961: Phase 1/2: Ixazomib + Pomalidomide + Dexamethasone In MM

Ixazomib + Pomalidomide + Dexamethasone In MM

This is a Phase I/II study using the combination of twice weekly ixazomib plus pomalidomide and dexamethasone in relapsed and or refractory multiple myeloma (RRMM) patients.

Sponsor

Paul G. Richardson, MD

Collaborator

Takeda

Information provided by (Responsible Party)

Paul G. Richardson, MD, Dana-Farber Cancer Institute

---

ClinicalTrials.gov Identifier: NCT04094961

Official Title: Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed/or Refractory Multiple Myeloma

First Posted: September 19, 2019

Click here to see details on ClinicalTrials.gov

---

Drug: Ixazomib

Drug: Pomalidomide

Drug: Dexamethasone

---

Ixazomib: National Cancer Institute

Ixazomib: MedlinePlus Drug Information

---

Location

United States, Massachusetts